Thomas Ingolia has become the new CEO of Myriad Proteomics, based in Salt Lake City, replacing acting CEO Peter Meldrum. He started his new appointment this week. Most recently, Ingolia was working as a consultant for biopharma. Prior to that, he was president of Microbia of Cambridge, Mass. Before that, he held positions at Ontogeny, based in Cambridge, which subsequently became Curis. He also served in various positions at Eli Lilly.